Brittany Lasseigne

Dr. Brittany Lasseigne

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Science
Verified
Journal Article
Closed access
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
BLBrittany Lasseigne
Brittany Lasseigne
SPSlavé Petrovski
Slavé Petrovski
PSPeter C. Sapp
Peter C. Sapp
PDPatrick A. Dion
Patrick A. Dion
DGDavid B. Goldstein
David B. Goldstein
New players in Lou Gehrig's disease: Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig's disease,” is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Cirulli et al. sequenced the expressed genes of nearly 3000 ALS patients and compared them with those of more than 6000 controls (see the Perspective by Singleton and Traynor). They identified several proteins that were linked to disease in patients. One such protein, TBK1, is implicated in innate immunity and autophagy and may represent a therapeutic target. Science , this issue p. 1436 ; see also p. 1422

28 July 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
RRRyne C. Ramaker
Ryne C. Ramaker
KBKevin M. Bowling
Kevin M. Bowling
BLBrittany Lasseigne
Brittany Lasseigne
MHMegan H Hagenauer
Megan H Hagenauer
AHAndrew A. Hardigan
Andrew A. Hardigan
RMRichard M. Myers
Richard M. Myers
Psychiatric disorders are multigenic diseases with complex etiology that contribute significantly to human morbidity and mortality. Although clinically distinct, several disorders share many symptoms, suggesting common underlying molecular changes exist that may implicate important regulators of pathogenesis and provide new therapeutic targets. We performed RNA sequencing on tissue from the anterior cingulate cortex, dorsolateral prefrontal cortex, and nucleus accumbens from three groups of 24 patients each diagnosed with schizophrenia, bipolar disorder, or major depressive disorder, and from 24 control subjects. We identified differentially expressed genes and validated the results in an independent cohort. Anterior cingulate cortex samples were also subjected to metabolomic analysis. ChIP-seq data were used to characterize binding of the transcription factor EGR1. We compared molecular signatures across the three brain regions and disorders in the transcriptomes of post-mortem human brain samples. The most significant disease-related differences were in the anterior cingulate cortex of schizophrenia samples compared to controls. Transcriptional changes were assessed in an independent cohort, revealing the transcription factor EGR1 as significantly down-regulated in both cohorts and as a potential regulator of broader transcription changes observed in schizophrenia patients. Additionally, broad down-regulation of genes specific to neurons and concordant up-regulation of genes specific to astrocytes was observed in schizophrenia and bipolar disorder patients relative to controls. Metabolomic profiling identified disruption of GABA levels in schizophrenia patients. We provide a comprehensive post-mortem transcriptome profile of three psychiatric disorders across three brain regions. We highlight a high-confidence set of independently validated genes differentially expressed between schizophrenia and control patients in the anterior cingulate cortex and integrate transcriptional changes with untargeted metabolite profiling.

24 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JMJoy M. McDaniel
Joy M. McDaniel
KVKatherine E. Varley
Katherine E. Varley
JGJason Gertz
Jason Gertz
DSDaniel S. Savic
Daniel S. Savic
BRBrian S. Roberts
Brian S. Roberts
RMRichard M. Myers
Richard M. Myers
Genomic regulation of invasion by STAT3 in triple negative breast cancer Genomic regulation of invasion by STAT3 in triple negative breast cancer

1 May 2020 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JCJ. Nicholas Cochran
J. Nicholas Cochran
EGEthan G. Geier
Ethan G. Geier
LBLuke W. Bonham
Luke W. Bonham
JNJ. Scott Newberry
J. Scott Newberry
MAMichelle D. Amaral
Michelle D. Amaral
JYJennifer S. Yokoyama
Jennifer S. Yokoyama

17 April 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MKMarie K. Kirby
Marie K. Kirby
RRRyne C. Ramaker
Ryne C. Ramaker
BRBrian S. Roberts
Brian S. Roberts
BLBrittany Lasseigne
Brittany Lasseigne
DGDavid S. Gunther
David S. Gunther
RMRichard M. Myers
Richard M. Myers
Current diagnostic tools for prostate cancer lack specificity and sensitivity for detecting very early lesions. DNA methylation is a stable genomic modification that is detectable in peripheral patient fluids such as urine and blood plasma that could serve as a non-invasive diagnostic biomarker for prostate cancer. We measured genome-wide DNA methylation patterns in 73 clinically annotated fresh-frozen prostate cancers and 63 benign-adjacent prostate tissues using the Illumina Infinium HumanMethylation450 BeadChip array. We overlaid the most significantly differentially methylated sites in the genome with transcription factor binding sites measured by the Encyclopedia of DNA Elements consortium. We used logistic regression and receiver operating characteristic curves to assess the performance of candidate diagnostic models. We identified methylation patterns that have a high predictive power for distinguishing malignant prostate tissue from benign-adjacent prostate tissue, and these methylation signatures were validated using data from The Cancer Genome Atlas Project. Furthermore, by overlaying ENCODE transcription factor binding data, we observed an enrichment of enhancer of zeste homolog 2 binding in gene regulatory regions with higher DNA methylation in malignant prostate tissues. DNA methylation patterns are greatly altered in prostate cancer tissue in comparison to benign-adjacent tissue. We have discovered patterns of DNA methylation marks that can distinguish prostate cancers with high specificity and sensitivity in multiple patient tissue cohorts, and we have identified transcription factors binding in these differentially methylated regions that may play important roles in prostate cancer development.

18 May 2018 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
BLBrittany Lasseigne
Brittany Lasseigne
JBJames D Brooks
James D Brooks